Arcutis Biotherapeutics stock poised for growth with 196% sales increase in skin drug sales

Thursday, Jul 17, 2025 12:30 pm ET1min read

Arcutis Biotherapeutics stock is trending higher in a base after reporting a 196% growth in skin disorder drug sales. The biotech company's bottom line is improving, with expected profitability on the horizon. As a result, Arcutis is an IBD 50 Growth Stocks To Watch pick for Thursday.

Arcutis Biotherapeutics stock poised for growth with 196% sales increase in skin drug sales

Comments



Add a public comment...
No comments

No comments yet